Arcturus Therapeutics Stands Out in mRNA Space – B. Riley Initiates Buy with $22 Price Target

B. Riley starts coverage on Arcturus Therapeutics with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.